Study Demonstrated Significant Efficacy and No Serious Adverse Events PHOENIX , May 18, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced positive top line pilot study results for the StemSpine ®... Read More

Initial experiments demonstrate expeditious potential for high-volume production of ImmCelz® with consistent potency Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy,... Read More

Creative Medical Technology Holdings, Inc. (OTC-CELZ) (the "Company"), a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications, today announced its intention to effect... Read More

Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today proof of concept data demonstrating the ability of its next generation ImmCelz ™ immunotherapy product to "reprogram" patient immune cells using the Company's patent pending "ex vivo cell-free" reprogramming protocol. The study was performed at cGMP Advanced... Read More

Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called "exosomes" secreted by cells of its MyeloCelz™ platform and their use in the treatment of type 1 diabetes. The patent additionally covers combinations of these antigen-specific exosomes together... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has engaged Elite Med Listings Inc. to help accelerate the adoption of CaverStem ® . Elite Med Listings is an agency... Read More

Creative Medical Technology Holdings, Inc . ("CELZ," the "Company", "we", "our" or "us") (OTC: CELZ) today announced that it has entered into definitive agreements with accredited institutional investors for gross proceeds of approximately $3,788,000 . The definitive agreements provide for the private placement of 15% Original... Read More

Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today the launching of its second Regenerative Immunology product, MyeloCelz™. In contrast to the Company's ImmCelz™ product, which utilizes primarily T cells and B cells to induce activation of the body's own stem cells and healing processes, MyeloCelz™ utilizes... Read More

Creative Medical Technology Holdings (OTC-CELZ) announced today recruitment of Dr. Courtney Bartlett to lead clinical development of the Company's pipeline of therapeutic products. Dr. Bartlett has been heading clinical research efforts for more than a decade in the area of cell and gene therapy. She was co-Investigator on... Read More

Creative Medical Technology Holdings, Inc. (OTC - CELZ), announced that the company will virtually present at the Investor Forum at the World Stem Cell Summit today Thursday, June 17, 2021 at 12:00pm Eastern Standard Time and will consist of a 20-minute formal description of the Company followed by a 20-minute Q&A session... Read More

Creative Medical Technology Holdings , trading under Ticker Symbol CELZ, announced the filing of a provisional patent application in connection with new data indicating that the Company's ImmCelz® personalized cell therapy product and myeloid suppressor cells suppress autoimmune diabetes. In a series of experiments,... Read More

Creative Medical Technology Holdings , trading under ticker symbol CELZ, announced today positive preclinical data supporting extension of ImmCelz® applicability to Parkinson's Disease. Using the well established MPTP mouse model of the disease, it was demonstrated that administration of ImmCelz® inhibited onset of... Read More

Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company's Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs Timothy Henry , Santosh Kesari , Ceagan Du, and Boris Reznik in accelerating advancement of its ImmCelz® Regenerative Immunotherapy... Read More

Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced today receipt of detailed correspondence from the FDA regarding necessary modifications to IND #27375 for using ImmCelz® regenerative immunotherapy for the treatment of stroke. The Company's ImmCelz® product utilizes a patient's own blood cells that have been "reprogrammed" in the laboratory by culturing with established universal donor... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to launch Virtual Physician™ focused on telehealth solutions for regenerative medicine this summer. The... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that the FDA issued IND Number 27375 to the Company in connection with its Clinical Trial application to use ImmCelz ®... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has started recruitment of clinical sites for StemSpine®. StemSpine® , the company's patented Regenerative... Read More

Creative Medical Technology Holdings (OTC - CELZ) announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease. Evaluation of patients at 30,60 90, 180, and 360... Read More

Creative Medical Technology Holdings (OTC-CELZ) announced today that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz® Investigational New Drug Application (IND) for the treatment of Stroke will be resubmitted to the FDA in electronic form to comply with such requirements.... Read More

Creative Medical Technology Holdings , Inc. (OTC – CELZ) announced today filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of transplanted organs. ImmCelz® is a cellular therapy that prevents pathological immunity and inflammation while at the same time inducing regeneration of damaged tissue. Mechanistically ImmCelz® has been shown to function through stimulation... Read More